Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15; 22(6):1025-33.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Androgen Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
Humans
Hydrocortisone
Ketoconazole
Male
Prospective Studies
Prostate-Specific Antigen
Prostatic Neoplasms
Survival Analysis

authors with profiles

Walter M. Stadler